Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 15/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.32 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718151 | 1.00 | SLC5A2 (0.36) | SLC5A2ABCB11ADORA3SLC5A1SLC6A4 | |
| SCHEMBL4718546 | 0.87 | TRPM5 (0.41) | SLC5A2SLC5A1SLC6A3LGALS3TRPM4 | |
| SCHEMBL4986893 | 0.82 | SLC5A2 (0.50) | SLC5A2 | |
| SCHEMBL4087278 | 0.82 | SLC5A2 (0.50) | SLC5A2 | |
| SCHEMBL4987870 | 0.82 | SLC5A2 (0.50) | SLC5A2 | |
| SCHEMBL4717027 | 0.82 | SLC5A2 (0.50) | SLC5A2 | |
| SCHEMBL19329994 | 0.79 | EPHX1 (0.43) | SLC5A2ABCB11ADORA3SLC5A1SLC6A4 | |
| SCHEMBL4077235 | 0.79 | EPHX1 (0.43) | SLC5A2ABCB11ADORA3SLC5A1SLC6A4 | |
| SCHEMBL4086552 | 0.79 | EPHX1 (0.43) | SLC5A2ABCB11ADORA3SLC5A1SLC6A4 | |
| SCHEMBL4078798 | 0.75 | SLC5A2 (0.46) | SLC5A2SLC5A1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638512-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-7517899-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080255102-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-7414052-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1730127-B1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080146645-A1 | Process for Preparing Indolinone Phenylaminopropanol Derivatives | WYETH (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146645-A1 | Process for Preparing Indolinone Phenylaminopropanol Derivatives | WYETH (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146645-A1 | Process for Preparing Indolinone Phenylaminopropanol Derivatives | WYETH (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008024492-A2 | INDOLINONE PHENYLAMINOPROPANOL DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | WYETH (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1732887-B1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007041023-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1732887-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1730127-A1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth, A Corporation of the State of Delaware (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005097744-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097761-A1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050222142-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | COMT, PNMT, GLS | SLC5A2 48/4885ABCB11 1814/4885ADORA3 1470/4885 |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | SLC5A2 80/4885ABCB11 971/4885ADORA3 1226/4885 |
| US-20080146645-A1 | Process for Preparing Indolinone Phenylaminopropanol Derivatives | IDO1, CYP1A1, IDO2 | SLC5A2 4261/4885ABCB11 946/4885ADORA3 581/4885 |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | SLC5A2 80/4885ABCB11 971/4885ADORA3 1226/4885 |
| US-20050222142-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | SLC5A2 80/4885ABCB11 971/4885ADORA3 1226/4885 |
| US-20080255102-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | SLC5A2 30/4885ABCB11 777/4885ADORA3 845/4885 |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | SLC5A2 80/4885ABCB11 971/4885ADORA3 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.